Stai navigando con un browser obsoleto. per favore aggiorna il tuo browser per migliorare la tua esperienza e la tua sicurezza.

CDP Venture Capital
Milano Life Science


InnovHeart, with locations in Milan, Italy, and Boston, Massachusetts, develops transcatheter mitral valve replacement (TMVR) systems to treat patients suffering from mitral valve disease. About 2% of the world's population, in fact, suffers from mitral valve dysfunctions, which manifest themselves with the reflux of blood from the left ventricle to the left atrium, due to an anomaly that results in an imperfect coaptation of the mitral flaps during ventricular sistole. 
Our company mission is to bring patients a novel therapeutic system suitable to replace incompetent Mitral Valves based on a safe, effective, and easy-to-use transcatheter technology. InnovHeart is committed to pursuing this goal with the highest level of quality, minimizing the functional limitations of the competitors’ devices and implanting its technology through a less invasive procedure, avoiding surgical preparation for the patient. 
The company is currently in clinical trials testing its TMVR Saturn Prosthesis, designed to be consistent with the anatomy of the mitral valve. Saturn is a low-profile prosthetic designed for both Trans-apical and Trans-septal delivery.

The ecosystem supporting innovation in Italy